Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-26T09:30:50.008Z Has data issue: false hasContentIssue false
  • English
  • Français

Action, Not Rhetoric, Needed to Reverse the Opioid Overdose Epidemic

Published online by Cambridge University Press:  01 January 2021

Corey Davis ,
Traci Green  and
Leo Beletsky
Get access Rights & Permissions [Opens in a new window]

Abstract

Despite shifts in rhetoric and some positive movement, Americans with the disease of addiction are still often stigmatized, criminalized, and denied access to evidencebased care. Dramatically reducing the number of lives unnecessarily lost to overdose requires an evidence-based, equity-focused, well-funded, and coordinated response. We present in this brief article evidence-based and promising practices for improving and refocusing the response to this simmering public health crisis. Topics covered include improving clinical decision-making, improving access to non-judgmental evidence-based treatment, investing in comprehensive public health approaches to problematic drug use, and changing the way law enforcement actors interact with people who use drugs.

Type
Symposium Articles
Information
Journal of Law, Medicine & Ethics , Volume 45 , Issue S1: 2016 Public Health Law Conference — Lead, Connect, Innovate: Strategies for Achieving Health Equity , Spring 2017 , pp. 20 - 23
Copyright
Copyright © American Society of Law, Medicine and Ethics 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Office of National Drug Control Policy, Epidemic: Responding to America's Prescription Drug Abuse Crisis (2011), Office of National Drug Control Policy.Google Scholar
Centers for Disease Control and Prevention, Number and Age-Adjusted Rates of Drug-Poisoning Deaths Involving Opioid Analgesics and Heroin: United States, 2000–2014 (2015).Google Scholar
Park, H. and Bloch, M., “How the Epidemic of Drug Overdose Death Ripples Across America,” New York Times, January 19, 2016.Google Scholar
McLean, K., “There's Nothing Here”: Deindustrialization as Risk Environment for Overdose,” International Journal of Drug Policy no. 29 (2016): 19-26; K. M. Keyes, M. Cerda, J. E. Brady, J. R. Havens, and S. Galea, “Understanding the Rural-Urban Differences in Nonmedical Prescription Opioid Use and Abuse in the United States,” American Journal of Public Health 104, no. 2 (2014): e52-e59; A. Case and A. Deaton, “Rising Morbidity and Mortality in Midlife among White Non-Hispanic Americans in the 21st Century,” Proceedings of the Nationall Academy of Science 112, no. 49 (2015): 15078-15083; L. R. Webster, S. Cochella, N. Dasgupta, K. L. Fakata, P. G. Fine, S. M. Fishman, T. Grey, E. M. Johnson, L. K. Lee, S. D. Passik, J. Peppin, C. A. Porucznik, A. Ray, S. H. Schnoll, R. L. Stieg, and W. Wakeland, “An Analysis of the Root Causes for Opioid-Related Overdose Deaths in the United States,” Pain Medicine 12, Supp. 2 (2011): S26-35.CrossRefGoogle Scholar
Kertesz, S. G., “Turning the Tide or Riptide? The Changing Opioid Epidemic,” Substance Abuse (November 18, 2016): 1-6.CrossRefGoogle Scholar
Hedegaard, H., Chen, L. H., and Warner, M., “Drug-Poisoning Deaths Involving Heroin: United States, 2000-2013,” NCHS Data Brief 190 (2015):1-8.Google Scholar
Green, T. C., and Gilbert, M., “Counterfeit Medications and Fentanyl,” JAMA Intern Medicine 176, no. 10 (2016): 1557-1557.CrossRefGoogle Scholar
Bourgois, P., “Crack and the Political Economy of Social Suffering,” Addiction Research & Theory 11, no. 1 (2009): 31-37.CrossRefGoogle Scholar
Davis, C. S., Green, T. C., and Zaller, N. D., “Addressing the Overdose Epidemic Requires Timely Access to Data to Guide Interventions,” Drug and Alcohol Review 35, no. 4 (2016): 383-386.CrossRefGoogle Scholar
Tsang, A., Von Korff, M., Lee, S., Alonso, J., Karam, E., Angermeyer, M. C., Borges, G. L., Bromet, E. J., Demytteneare, K., de Girolamo, G., de Graaf, R., Gureje, O., Lepine, J. P., Haro, J. M., Levinson, D., Browne, M. A. Oakley, Posada-Villa, J., Seedat, S., and Watanabe, M., “Common Chronic Pain Conditions in Developed and Developing Countries: Gender and Age Differences and Comorbidity with Depression-Anxiety Disorders,” Journal of Pain 9, no. 10 (2008): 883-891.CrossRefGoogle Scholar
Chiu, J., Davis, C., and Burris, S., “Access to Therapeutic Opioids: A Plan of Action for Donors, NGOs, and Governments,” Temple International & Comparative Law Journal 24, no. 2 (2011): 101-130; G. Newshan and J. A. Staats, “Evidence-Based Pain Guidelines in HIV Care,” Journal of the Association of Nurses in AIDS Care 24, Supp. 1 (2013): S112-S126.Google Scholar
Franklin, G. M. and the American Academy of Neurology, “Opioids for Chronic Noncancer Pain: A Position Paper of the American Academy of Neurology,” Neurology 83, no. 14 (2014): 1277-1284.CrossRefGoogle Scholar
Dowell, D., Haegerich, T. M., and Chou, R., “CDC Guideline for Prescribing Opioids for Chronic Pain–United States, 2016,” JAMA 315, no. 15 (2016): 1624-1645.CrossRefGoogle Scholar
Kolodny, A., Courtwright, D. T., Hwang, C. S., Kreiner, P., Eadie, J. L., Clark, T. W., and Alexander, G. C., “The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction,” Annual Review of Public Health 36 (2015): 559-574.CrossRefGoogle Scholar
Bernabei, R., Gambassi, G., Lapane, K., Landi, F., Gatsonis, C., Dunlop, R., Lipsitz, L., Steel, K., and Mor, V., “Management of Pain in Elderly Patients with Cancer. SAGE Study Group. Systematic Assessment of Geriatric Drug Use via Epidemiology,” JAMA 279, no. 23 (1998): 1877-1882; S. H. Meghani, E. Byun, and R. M. Gallagher, “Time to Take Stock: A Meta-analysis and Systematic Review of Analgesic Treatment Disparities for Pain in the United States,” Pain Medicine 13, no. 2 (2012): 150-174.CrossRefGoogle Scholar
Davis, C. S. and Carr, D., “Physician Continuing Education to Reduce Opioid Misuse, Abuse, and Overdose: Many Opportunities, Few Requirements,” Drug and Alcohol Dependence 163 (2016): 100-107.CrossRefGoogle Scholar
Walley, A. Y., Xuan, Z., Hackman, H. H., Quinn, E., Doe-Simkins, M., Sorensen-Alawad, A., Ruiz, S., and Ozonoff, A., “Opioid Overdose Rates and Implementation of Overdose Education and Nasal Naloxone Distribution in Massachusetts: Interrupted Time Series Analysis,” BMJ 346 (2013): f174.CrossRefGoogle Scholar
Substance Abuse and Mental Health Services Administration, Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings (2014); Davis, C. S. and Carr, D., “Legal Changes to Increase Access to Naloxone for Opioid Overdose Reversal in the United States,” Drug and Alcohol Dependence 157 (2015): 112-120.CrossRefGoogle Scholar
Rutkow, L. and Davis, C. S., “Opportunities to Improve Decision-Making about Opioid Prescribing,” Journal of General Internal Medicine 32, no. 1 (2017): 3-5.CrossRefGoogle Scholar
Brody, J., “Effective Addiction Treatment,” New York Times, February 4, 2013.Google Scholar
Executive Office of the President, National Drug Control Strategy: FY 2016 Budget and Performance Summary (2015).Google Scholar
Strathdee, S. A., Beletsky, L., and Kerr, T., “HIV, Drugs and the Legal Environment,” International Journal of Drug Policy 26, Supp. 1 (2015): S27-S32; C. S. Davis, S. Burris, J. Kraut-Becher, K. G. Lynch, and D. Metzger, “Effects of an Intensive Street-Level Police Intervention on Syringe Exchange Program Use in Philadelphia, PA,” American Journal of Public Health 95, no. 2 (2005): 233-236.CrossRefGoogle Scholar
Tempalski, B., Flom, P. L., Friedman, S. R., Des Jarlais, D. C., Friedman, J. J., McKnight, C., and Friedman, R., “Social and Political Factors Predicting the Presence of Syringe Exchange Programs in 96 US Metropolitan Areas,” American Journal of Public Health 97, no. 3 (2007): 437-447.CrossRefGoogle Scholar